Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

In a major step forward in the fight against HIV/AIDS, the US Food and Drug Administration (FDA) has approved Lenacapavir, an ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...